Benefit of Cusp overlap method for self‐expanding transcatheter aortic valves

The need for permanent pacemaker implantation (PPM) continues to be one of the main challenges in TAVR, especially with self-expanding valves, with a pacemaker implantation rate that varies between 17.5% and 30% in large randomized studies, vs. 4% to 6.5% with self-expanding valves.

Beneficio del implante alto de las válvulas aórticas percutáneas autoexpandibles 

Therefore, in an attempt to prevent the need for PPM implantation, the cusp overlapping technique has been developed (COT) which several analysts have shown has a lower rate vs the conventional implantation technique also called three cusp technique (3C). However, at present, this technique still calls for robust, large randomized trials. 

This study looked at 647 patients undergoing TAVR with self-expanding EVOLUT; 519 (80.2%) with the COT technique.

Both groups were similar, with mean age 82, but surgical scores were higher in those treated with the 3C technique. 

Left ventricular function was higher in COT patients (58% vs. 53%, p<0.001), with 41 mmHg gradient and close to 2% bicuspid valves. 

Read also: Does Post-Dilation in TAVR Affect its Long-Term Outcomes?

Valve 29 was the most used (45%), followed by the 26 (35%), and 34 (12%) and, in lower numbers, the 23; the transfemoral approach was used in nearly all patients.

At 30 days, patients treated with the COT technique showed lower need for PPM implantation (10% vs. 21%, p=<0.001) and one new AV block (11% vs. 23%, p<0.001), with no difference in new intraventricular conduction block. 

Conclusion

COT presents some potential technical advantages vs. 3C, and perhaps a lower rate of PPM implantation in TAVR with self-expanding EVOLUT. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Cusp overlap method for self‐expanding transcatheter aortic valve replacement.

Reference: Talal F. Aljabbary, et al. Catheter Cardiovasc Interv. 2024;103:202–208.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....